5月23日,科伦博泰生物-B(06990)发布公告,宣布公司已收到根据与Windward Bio AG关于SKB378/HBM9378/WIN378的许可协议支付的首付款。该首付款包括现金及Windward Bio母公司的股权,其中现金款项于2025年2月收到,而股权将在获得中国境内相关监管批准并满足其他交割条件后于2025年5月完成交割。
SKB378/HBM9378/WIN378是公司与和铂医药共同开发的项目,双方平分全球权利。这是一种新型的重组全人源单克隆抗体,能有效结合TSLP配体,抑制TSLP介导的信号通路,且已获得国家药品监督管理局(NMPA)批准用于治疗慢性阻塞性肺疾病的IND申请。公司已完成在中国健康受试者中开展的用于治疗中度及重度哮喘的一期临床试验,Windward Bio正在准备二期试验。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.